top of page

Post-Market Surveillance and PSUR: PMS System, PMS Plan, PMS Report and Update Frequency

12 hours ago
8 min read
PSUR ve piyasaya arz sonrası gözetim sistemi

SUMMARY

The PSUR (periodic safety update report) is the report in which manufacturers of class IIa, class IIb and class III devices summarize the results of the analysis of their post-market surveillance (PMS) data. For class I devices, a PMS report is prepared instead of a PSUR.

In the Tıbbi Cihaz Yönetmeliği (Medical Devices Regulation), these provisions are in Articles 81-84; their counterparts in Regulation (EU) 2017/745 (MDR) are Articles 83-86. In this article we give the PMS system, the plan, the reports and the update frequencies as direct quotations from the regulation text.

For the ÜTS registration and individual notifications of your devices: Medical Device ÜTS Registration Consultancy

Contents

1. What Is Post-Market Surveillance?

Article 3 of the Tıbbi Cihaz Yönetmeliği:

“(uu) Post-market surveillance: all activities carried out by manufacturers, in cooperation with other economic operators, to institute and keep up to date a systematic procedure to proactively collect and review experience gained from devices they place on the market, make available on the market or put into service, for the purpose of identifying any need to immediately apply any necessary corrective or preventive actions,”

For a short explanation of the concept, see our page on what is post-market surveillance.

2. PMS System: Article 81

“(1) For each device, manufacturers shall plan, establish, document, implement, maintain and update a post-market surveillance system in a manner that is proportionate to the risk class and appropriate for the type of device. That system shall be an integral part of the manufacturer's quality management system referred to in the ninth paragraph of Article 10.”

Under the second paragraph, the system shall be suited to:

  • “a) actively and systematically gathering, recording and analysing relevant data on the quality, performance and safety of a device throughout its lifetime,”

  • “b) drawing the necessary conclusions,”

  • “c) determining, implementing and monitoring preventive and corrective actions,”

Under the third paragraph, the data gathered is used in particular for the following purposes:

  • “a) to update the benefit-risk determination and to improve risk management as referred to in Chapter I of Annex I,”

  • “b) to update the design and manufacturing information, the instructions for use and the labelling,”

  • “c) to update the clinical evaluation,”

  • “ç) to update the summary of safety and clinical performance referred to in Article 32,”

  • “d) to identify needs for preventive, corrective or field safety corrective action,”

  • “e) to identify options to improve the usability, performance and safety of the device,”

  • “f) when relevant, to contribute to the post-market surveillance of other devices,”

  • “g) to detect and report trends in accordance with Article 86.”

“The technical documentation shall be updated accordingly.”

“(4) If, during the post-market surveillance, a need for preventive action, corrective action, or both is identified, manufacturers shall implement the appropriate measures and inform the Agency, the other competent authorities concerned and, where applicable, the notified body. Where a serious adverse event is identified or a field safety corrective action is implemented, it shall be reported in accordance with Article 85.”

For the notifications under Article 85, see our article on vigilance and serious adverse event reporting.

3. PMS Plan: Article 82 and Annex III

“(1) The post-market surveillance system referred to in Article 81 shall be based on a post-market surveillance plan, the requirements for which are set out in point 1 of Annex III. For devices other than custom-made devices, the post-market surveillance plan shall be part of the technical documentation specified in Annex II.”

Under point 1 of Annex III, the plan addresses in particular the collection and use of the following available information:

  • “- information concerning serious adverse events and field safety corrective actions, including information from periodic safety update reports,”

  • “- records referring to non-serious adverse events and data on any undesirable side-effects,”

  • “- information from trend reporting,”

  • “- relevant specialist or technical literature, databases and/or registers,”

  • “- information, including feedback and complaints, provided by users, distributors and importers, and”

  • “- publicly available information about similar medical devices.”

One of the items in the minimum content of the plan:

“- suitable indicators and threshold values that shall be used in the continuous reassessment of the benefit-risk analysis and of the risk management as referred to in point 3 of Annex I,”

4. Class I Devices: PMS Report

“(1) Manufacturers of class I devices shall prepare a post-market surveillance report summarising the results and conclusions of the analyses of the post-market surveillance data gathered as a result of the post-market surveillance plan referred to in Article 82, together with a rationale and description of any preventive and corrective actions taken. The report shall be updated when necessary and made available to the Agency upon request.”

For class I, the regulation sets no fixed update interval: the report is updated when necessary and made available to the Agency upon request. For class I devices, see our article on class I medical devices.

5. Class IIa, IIb and III: PSUR Content

Point (a) of the first paragraph of Article 84:

“a) Manufacturers of class IIa, class IIb and class III devices shall prepare, for each device and, where relevant, for each category or group of devices, a periodic safety update report (PSUR) summarising the results and conclusions of the analyses of the post-market surveillance data gathered as a result of the post-market surveillance plan referred to in Article 82, together with a rationale and description of any preventive and corrective actions taken. Throughout the lifetime of the device concerned, the PSUR shall set out:”

  • “1) the conclusions of the benefit-risk determination,”

  • “2) the main findings of the post-market clinical follow-up,”

  • “3) the volume of sales of the device, an estimate evaluation of the size and other characteristics of the population using the device and, where practicable, the usage frequency of the device.”

For the post-market clinical follow-up in the second item, see our article on clinical evaluation and PMCF.

6. How Often Is the PSUR Updated?

  • “b) Manufacturers of class IIb and class III devices shall update the PSUR at least annually. That report shall, except in the case of custom-made devices, be part of the technical documentation as specified in Annex II and Annex III.”

  • “c) Manufacturers of class IIa devices shall update the PSUR when necessary and at least every two years. That report shall, except in the case of custom-made devices, be part of the technical documentation as specified in Annex II and Annex III.”

  • “ç) For custom-made devices, the PSUR shall be part of the documentation referred to in point 2 of Annex XIII.”

  • Class I: the PMS report is updated when necessary (Art. 83).

  • Class IIa: the PSUR is updated when necessary and at least every two years (Art. 84/1-c).

  • Class IIb and III: the PSUR is updated at least once a year (Art. 84/1-b).

For a short answer on frequency, see our page on who prepares the PSUR and how often it is submitted.

7. To Whom Is the PSUR Submitted?

“(2) For class III devices or implantable devices, manufacturers shall submit PSURs using the electronic system referred to in Article 89 to the notified body involved in the conformity assessment in accordance with Article 52. The notified body shall review the report and add its evaluation to the electronic system, with details of any action taken. Such PSURs and the notified body's evaluation shall be made available to the Agency and the other competent authorities through that electronic system.”

“(3) For devices other than those referred to in the second paragraph, manufacturers shall make PSURs available to the notified body involved in the conformity assessment and, upon request, to the Agency and the other competent authorities.”

8. EUDAMED Vigilance Module and Transition

The second paragraph of Article 84 applies six months after the date of publication of the notice that the relevant electronic system is functional, under point (a) of the first paragraph of Article 111. The EUDAMED Q&A text published in Turkish by TİTCK (Q13):

“The submission of the required PSURs (see the abbreviations section) and vigilance reports in Eudamed by manufacturers and authorised representatives, and of NCARs by CAs, will begin when use of the VGL module becomes mandatory.”

According to the footnote of the same text:

“In accordance with MDCG 2021-25 and MDCG 2022-21, legacy devices, custom-made devices and old devices do not require a PSUR in Eudamed.”

Under point (d) of the fifth paragraph of Provisional Article 1, the post-market surveillance requirements of this Regulation also apply to devices certified under the former regulations and placed on the market under the transitional provisions. For the EUDAMED registration of these devices, see our article on EUDAMED legacy device registration.

9. Trend Reporting: Article 86

Under the first paragraph of Article 86, manufacturers report through the electronic system any statistically significant increase in the frequency or severity of incidents that are not serious adverse events or that are expected undesirable side-effects. The method is set out in the PMS plan:

“The manufacturer shall specify in the post-market surveillance plan referred to in Article 82 how it will manage the incidents described in this paragraph, as well as the methodology used for determining any statistically significant increase in the frequency or severity of such incidents, and the observation period.”

10. PMS Report and PSUR for IVD Devices

The In Vitro Tanı Amaçlı Tıbbi Cihaz Yönetmeliği (In Vitro Diagnostic Medical Devices Regulation) provides for a PMS report for class A and B devices (Art. 80) and a PSUR for class C and D devices (Art. 81):

“b) Manufacturers of class C and class D devices shall update the PSUR at least annually. That report shall be part of the technical documentation as specified in Annex II and Annex III.”

Instead of clinical follow-up, the IVD PSUR contains "the main findings of the post-market performance follow-up". For class D devices, the report is submitted to the notified body through the electronic system (Art. 81/2). For IVD registrations, see our article on ÜTS IVD product registration.

11. Frequently Asked Questions

Is a PMS report the same thing as a PSUR?

No. Under Article 83 of the Tıbbi Cihaz Yönetmeliği, the PMS report is prepared for class I devices; under Article 84, the PSUR is prepared for class IIa, IIb and III devices.

Is a PSUR prepared for a class I device?

No. The manufacturer of a class I device prepares a PMS report under Article 83; the report is updated when necessary and made available to the Agency upon request.

How often is the PSUR updated?

Under Article 84, at least once a year for class IIb and III devices, and when necessary and at least every two years for class IIa devices.

Is the PMS plan part of the technical file?

Yes. Under Article 82, for devices other than custom-made devices, the PMS plan is part of the technical documentation specified in Annex II.

When is the PSUR submitted to EUDAMED?

According to the EUDAMED Q&A text published in Turkish by TİTCK, the submission of PSURs in EUDAMED begins when use of the VGL module becomes mandatory. Legacy devices, custom-made devices and old devices do not require a PSUR in EUDAMED.

For the ÜTS registration and individual notifications of your devices: Medical Device ÜTS Registration Consultancy

Sources

 
 

Medical Device ÜTS Registration Consultancy

Request an ÜTS registration consultancy quote

Ehlibeyt Mahallesi, Tekstilciler Caddesi No: 35/7 06520 Çankaya / Ankara - TÜRKİYE

Cevizli Mahallesi, Zuhal Caddesi Ritim İstanbul B Blok, No:44 Maltepe / İstanbul - TÜRKİYE

info@medexmedikal.com
+90 505 580 4622
+90 312 389 1354

ÜTS Guides · Legislation Calendar · Glossary · ÜTS Guide Index · Frequently Asked Questions

Services: ÜTS Consultancy · Who Carries Out the ÜTS Registration? · ÜTS Document Registration Consultancy · ÜTS Product Registration Consultancy · Importer ÜTS Registration Consultancy · Sales Centre Authorisation Certificate · EUDAMED Registration Consultancy · MDR/IVDR Declaration of Conformity · Technical File Preliminary Review · Label and Instructions for Use Check · PRRC Service · PMS and PSUR · Clinical Evaluation · EMDN and GMDN Code Determination · Certificate of Free Sale · EUDAMED XML Generator · ÜTS Registration Training · Correction of a Rejected ÜTS Application

KVKK and Privacy Policy | Cookie Policy | Accessibility Statement

© 2026 Medex Kurumsal Danışmanlık Ltd. Şti.

bottom of page
WhatsApp Hemen Ara